8-K: Stereotaxis Reports 39% Revenue Increase in Q4 2024, Cites Strategic Transformation

Stereotaxis reports a strong Q4 2024 with a 39% revenue increase and positive cash flow, driven by robotic system revenue and the integration of Access Point Technologies (APT).

Summary

• Stereotaxis reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company's Q4 revenue increased by 39% year-over-year, reaching $6.3 million compared to $4.6 million in the prior year.
• System revenue for the quarter was $1.4 million, while recurring revenue was $4.9 million.
• Full-year 2024 revenue totaled $26.9 million, slightly up from $26.8 million in 2023.
• The system backlog at the start of 2025 is $15.2 million.
• Gross margin for Q4 2024 was approximately 51%, and for the full year, it was 54%.
• Stereotaxis generated positive cash flow in the fourth quarter and ended the year with over $12 million in cash and no debt.
• The company anticipates double-digit revenue growth for the full year 2025.
• Recurring revenue is expected to scale throughout 2025, from $5 million in Q1 to $7 million in Q4.
• System revenue is expected to remain approximately flat with 2024, at $2-3 million per quarter.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the revenue growth, positive cash flow in Q4, and optimistic outlook for 2025. However, the operating and net losses temper the enthusiasm.

Positives

• The company experienced a significant revenue increase in Q4 2024.
• Stereotaxis achieved positive cash flow in the fourth quarter.
• The company has a strong cash position with no debt.
• Stereotaxis anticipates double-digit revenue growth in 2025.
• Recurring revenue is expected to increase throughout 2025.
• The company has a substantial system backlog of $15.2 million at the start of 2025.
• European regulatory approval of the MAGiC catheter, the first sale of the GenesisX robot, regulatory approvals for Genesis and Magbot in China, and regulatory submissions for MAGiC Sweep and EMAGIN 5F were achieved.

Negatives

• Operating loss and net loss in the fourth quarter of 2024 were ($7.6) million and ($7.5) million, respectively, compared to ($5.3) million and ($5.0) million in the previous year.
• System gross margins remain impacted by fixed overhead allocated over low production levels.
• Negative free cash flow for the full year 2024 was ($8.5) million compared to ($9.5) million for the full year 2023.

Risks

• The company's future performance is subject to risks, uncertainties, and other important factors that could cause actual results to differ materially from projections.
• The company's ability to manage expenses at sustainable levels is a risk factor.
• Acceptance of the company's products in the marketplace is a risk factor.
• The effect of global economic conditions on the ability and willingness of customers to purchase its technology is a risk factor.
• Dependence upon third-party vendors is a risk factor.
• Timing of regulatory approvals is a risk factor.
• There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Companys control and may be revised, modified, delayed, or canceled.

Future Outlook

Stereotaxis anticipates double-digit revenue growth for the full year 2025, with recurring revenue scaling throughout the year and system revenue remaining approximately flat. Reduced cash use is expected in 2025 compared to 2024.

Management Comments

• We have started a milestone rich year in which we will demonstrate the tangible reality of our overall strategic transformation into a company with an easily adopted robot that can navigate a proprietary set of catheters in EP and broadly across endovascular procedures, said David Fischel, Chairman and CEO.
• Our progress leads to an expanded clinical impact, scalable capital model, strategic self-sufficiency, and an attractive high-margin recurring catheter business.

Industry Context

Stereotaxis operates in the surgical robotics market, which is experiencing growth due to increasing demand for minimally invasive procedures. Competitors include companies like Intuitive Surgical and Medtronic, which also offer robotic systems for various surgical applications. Stereotaxis is focusing on the endovascular intervention segment, aiming to differentiate itself through its proprietary robotic technology and catheter systems.

Comparison to Industry Standards

• Intuitive Surgical, a leader in surgical robotics, reported revenue of $1.93 billion in Q4 2024, showcasing the scale of the broader surgical robotics market.
• Medtronic's cardiac rhythm and heart failure division, which includes some competing technologies, reported revenue of $1.5 billion in its most recent quarter.
• Stereotaxis' focus on endovascular intervention and its recurring revenue model are strategies employed by other medical device companies to ensure stable growth and profitability.

Stakeholder Impact

• Shareholders can expect potential value appreciation due to revenue growth and strategic initiatives.
• Employees may benefit from the company's expansion and commercialization efforts.
• Customers (physicians and hospitals) can anticipate access to innovative robotic systems and solutions.
• Suppliers may see increased demand for components and materials as production scales up.

Next Steps

• The company plans to advance its transformative product ecosystem to market.
• Stereotaxis intends to fund its commercialization efforts.
• The company aims to profitably grow its business.

Key Dates